Please assess the completion status of the following clinical trial:

Trial Title: Hepatic Impairment Study for Lorlatinib in Cancer Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed solid malignancy or lymphoma that is metastatic or unresectable, and for which standard curative or palliative measures do not exist, or are no longer effective;~* Biliary obstruction with a biliary drain or stent;~* Neurologically stable gliomas and brain metastases;~* ECOG performance status of 0, 1, or 2;~* adequate bone marrow function;~* adequate pancreatic function;~* adequate renal function;~* female patients with negative pregnancy test~Exclusion Criteria:~* untreated esophageal varices; uncontrolled ascites;~* episodes of hepatic encephalopathy within the last 4 weeks;~* spinal cord compression; major surgery within 4 weeks prior to enrollment;~* radiation therapy within 2 weeks prior to enrollment;~* last anti-cancer treatment within 2 weeks prior to screening;~* previous high-dose chemotherapy requiring stem cell rescue;~* prior to irradiation to \>25% of the bone marrow;~* gastrointestinal abnormalities;~* known prior or suspected hypersensitivity to lorlatinib or lorlatinib tablet;~* clinically significant bacterial, fungal or viral infections for non-liver cancer patients;~* clinically significant cardiovascular disease;~* uncontrolled hypertension; acute pancreatitis with predisposing characteristics;~* history of grade 3 or 4 interstitial fibrosis or interstitial lung disease;~* active hemoelysis or evidence of biliary sepsis;~* prior major gastrointestinal surgery;~* concurrent use of known strong CYP3A inhibitors, inducers and P-gp substrates with a narrow therapeutic index;~* concurrent use of CYP3A substrates with narrow therapeutic indices;~* prior treatment with lorlatinib; active bleeding disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A1 Normal hepatic function (Type: ACTIVE_COMPARATOR): continued daily administration of lorlatinib in patients with normal hepatic function
- Group A2 Normal hepatic function (Type: ACTIVE_COMPARATOR): continued daily administration of lorlatinib in patients with normal hepatic function
- Group B mild hepatic impairment (Type: EXPERIMENTAL): continued daily administration of lorlatinib in patients with mild hepatic impairment
- Group C moderate hepatic impairment (Type: EXPERIMENTAL): continued daily administration of lorlatinib in patients with moderate hepatic impairment
- Group D severe hepatic impairment (Type: EXPERIMENTAL): continued daily administration of lorlatinib in patients with severe hepatic impairment

Based on this trial design, predict the completion outcome and termination type (if applicable).